Pancreatic ductal adenocarcinoma: metastatic disease

被引：0
作者：
A. J. Muñoz Martín
J. Adeva
J. Martínez-Galán
J. J. Reina
M. Hidalgo
机构：
[1] Hospital General Universitario Gregorio Marañón,Department of Medical Oncology
[2] Hospital Universitario 12 de Octubre,Department of Medical Oncology
[3] Hospital Universitario Virgen de las Nieves,Department of Medical Oncology
[4] Hospital Universitario Virgen de la Macarena,Department of Medical Oncology
[5] Harvard University,Department of Medical Oncology, Beth Israel Deaconess Medical Center
来源：
Clinical and Translational Oncology | 2017年 / 19卷
关键词：
Pancreatic ductal adenocarcinoma; Metastatic; Management; Treatment sequencing; Re-evaluation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called “therapeutic sequencing” has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient’s characteristics.
引用
收藏
页码：1423 / 1429
页数：6
相关论文
共 133 条
  • [1] Hidalgo M(2015)Addressing the challenges of pancreatic cancer: future directions for improving outcomes Pancreatology 15 8-18
  • [2] Cascinu S(1999)Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database J Am Coll Surg 189 1-7
  • [3] Kleeff J(2001)Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Clin Infect Dis 33 139-144
  • [4] Labianca R(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
  • [5] Löhr J(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703
  • [6] Neoptolemos J(2014)Treatment of metastatic pancreatic adenocarcinoma: a review Oncology (Williston Park) 28 70-74
  • [7] Sener SF(2013)The impact of comorbidity on cancer survival: a review Clin Epidemiol 5 3-29
  • [8] Fremgen A(2015)Impact of comorbidity and age on determinants therapeutic strategies in advanced pancreatic head cancer patients with obstructive jaundices Medicine (Baltimore) 94 e1298-2787
  • [9] Menck HR(2000)Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565 J Clin Oncol 18 2780-3871
  • [10] Winchester D(2001)Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 3801-1979
12345678910